Submissions

Login or Register to make a submission.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
  • The submission is original and has not been previously published
  • Authors have used the Template to construct their manuscript before submission.
  • All the authors have read the version sent to the journal and agree with the submission
  • The main file is in Microsoft Word format (.docx)
  • Corresponding Author has provided his/her ORCID iD when Register

Author Guidelines

Authors should use a Template to construct their manuscripts before submission.

Original Articles should contain no more than 25 pages and not exceed 6,000 words. For Review Articles, until 9,000 words will be accepted. Manuscripts must be written using Microsoft Word for Windows, Times New Roman font, 10 points size and black color. Space between lines must be 1.0 without spacing before/after the paragraphs. Pages must be consecutively numbered, in the bottom right-hand corner of the page. Page’s margins should be moderate one (2.5 cm upper/lower, 1.9 cm left/right). The space between columns is 0.7 cm. Section titles must be written in bold style, 12 points size and subtitles in italic plus bold styles, 10 points size. Additional subsections must be written only in italic style.

The manuscript must be clear and concise. In addition to the original title, authors should submit one in abbreviated format. The Introduction section should identify in a clear and brief way, through using relevant references, the nature of the problem under investigation and the previous knowledge about it. Extensive literature review will not be accepted.

The Abstract should have no more than 250 words (Review and Original Articles). Write using times new roman font, 10 points size, justified.

For Keywords, authors should indicate 3 to 5 keywords separated by semicolon. Employ controlled vocabulary as indicated by DeCS at https://decs.bvsalud.org. Use times new roman font, 10 points size, justified, spacing 1.0.

The Experimental section should precede the Results and Discussion one. The Experimental section must describe in a clear and objective way the methodology used. The purity degree of reagents should be cited. Description of well-established procedures is not necessary. Supplementary section can be adopted and positioned before References. The instrumental applied should only be cited if not usual, indicating their brands and models.

Every experimental study on humans or animals must be proven to have the prior ethics approval of the appropriate institutional review body.

Unities of weight and measurements, names of plants, animals, and chemicals should be mentioned according to the International Rules available. Concentration expressions should be presented like the following example: mg.mL-1, mg.g-1.

Illustrations (photographs, charts, drawings, etc.) should be sent in separate files, in JPG format (at a high resolution - at least 300 dpi). They should be numbered consecutively with Arabic numerals, in the order that they are cited in the text and should be clear enough for reproduction and in the same language as the text. If there are figures extracted from other previously published studies, the authors should provide a written permission for their reproduction. This authorization shall accompany the manuscript submitted for publication. The figures must have title and subtitle (if necessary), which should be positions below the figure itself. The figures should be already inserted in the manuscript text body, but this does not exclude their sending in separate files. Large figures can be presented out of two column layout employing section break. When sending illustrations only in separate files, the figure captions should be listed in the last page of the manuscript.

Tables should be numbered consecutively, with Arabic numerals, in the order they were cited in the text and headed by a suitable title. Any extra information should be in under position in the table, as a footnote. Like illustrations, the tables should be already inserted in the manuscript text body always employing Microsoft Word for Windows and avoiding vertical lines. Large tables can be presented out of two column layout employing section break.

Abbreviations must be explained at first mention. On the rest of the article, it is not necessary to repeat the full name. Name of medications: the generic name should be used. In case of citing appliances/equipment: all item cited should include manufacturer's name, model, city, and country of manufacture. The authors can present all employed abbreviations in a footnote at the first page of the article.

Conclusions should summarize the main finding of the work and be written before Acknowledgements.

If there is any Conflict of interest, it should be declared. In case there is not, place in this section: "The authors declare no conflicts of interest" or "None to declare".

Sources of funding should be cited.

References should be numbered consecutively, in the order in which they are mentioned in the text, any identified with Arabic numerals (for example: 1-3, 5, 7). No spacing between paragraphs are required (DAR references style). The authors should ensure that the cited references in the text appear in the Reference list with exact dates and author's names correctly spelled. The accuracy of references is the author's responsibility. The recommended style for references is based on the National Information Standards Organization NISO Z39.29-2005 (R2010) Bibliographic References as adapted by the National Library of Medicine. Fuller explanations are in Citing Medicines https://www.nlm.nih.gov/bsd/uniform_requirements.html. Examples are described on Template.

 

Privacy Statement

Names and addresses informed here will be used exclusively for the services provided by this publication, and will not be made available for other purposes or to third parties.